IL-6 Inhibition as a Treatment for Noninfectious Uveitis - Takeaways - MDSpire

IL-6 Inhibition as a Treatment for Noninfectious Uveitis

Understanding interleukin-6 signaling sheds light on novel biologics that could benefit patients with refractory NIU.

  • By

  • Naveen Karthik, MD

  • Dilraj S. Grewal, MD, FASRS

  • September 1, 2025

  • 12 min

Share

  • 1

    Interleukin-6 (IL-6) is a proinflammatory cytokine involved in signaling pathways that promote inflammation in noninfectious uveitis (NIU).

  • 2

    Therapeutic agents targeting IL-6, including monoclonal antibodies, are being studied for their efficacy in treating refractory NIU.

  • 3

    Tocilizumab has shown significant efficacy in improving visual acuity and reducing macular edema in patients with refractory NIU.

  • 4

    Sarilumab demonstrated a significant decrease in vitreous haze and improved visual outcomes in patients with non-infectious uveitis.

  • 5

    Other IL-6 inhibitors, such as olokizumab and clazakizumab, are under investigation for their potential benefits in treating autoimmune conditions.

Original Source(s)

IL-6 Inhibition as a Treatment for Noninfectious Uveitis

  • by Naveen Karthik, MD, Dilraj S. Grewal, MD, FASRS

  • September 1, 2025

Related Content

The Benefits of Intravitreal Steroids During Vitrectomy

Triamcinolone acetonide enhances vitreous visualization, facilitates surgical maneuvers, and provides postoperative anti-inflammatory effects.

Targeting IL-6 in the Treatment of Uveitic Macular Edema

Why Uveitis Fellowship Deserves a Second Look

Uveitis Corner: Survey data and specialist insights challenge long-standing misconceptions about uveitis training, surgery, and compensation.